UBS Group
FRTX

UBS Group’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

UBS Group’s Portfolio FRTX Stock Details FRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-6,462
Closed -$4.26K – 10078
2023
Q1 		$4.26K Buy
6,462
+5,838
+936% +$9.74K ﹤0.01% 8211
2022
Q4 		$936 Buy
624
+347
+125% +$613 ﹤0.01% 10027
2022
Q3 		$1K Sell
277
-3,582
-93% -$10.4K ﹤0.01% 10135
2022
Q2 		$22K Buy
3,859
+3,370
+689% +$30.5K ﹤0.01% 6783
2022
Q1 		$6K Sell
489
-213
-30% -$2.3K ﹤0.01% 9029
2021
Q4 		$7K Buy
702
+235
+50% +$4.22K ﹤0.01% 9191
2021
Q3 		$15K Sell
467
-1,753
-79% -$56.9K ﹤0.01% 7531
2021
Q2 		$95K Buy
+2,220
New +$91.3K ﹤0.01% 5925
2021
Q1 		– Sell
-74
Closed -$4.06K – 9634
2020
Q4 		$3K Sell
74
-672
-90% -$21.1K ﹤0.01% 8034
2020
Q3 		$30K Buy
+746
New +$29.3K ﹤0.01% 6004
2019
Q4 		– Sell
-18
Closed -$3K – 8509
2019
Q3 		$3K Buy
+18
New +$4.13K ﹤0.01% 7676
2019
Q2 		– Sell
-39
Closed -$15K – 8247
2019
Q1 		$15K Buy
39
+37
+1,850% +$12.4K ﹤0.01% 6557
2018
Q4 		$1K Sell
2
-14
-88% -$5.49K ﹤0.01% 7930
2018
Q3 		$7K Buy
16
+8
+100% +$3.37K ﹤0.01% 7354
2018
Q2 		$3K Sell
8
-35
-81% -$16.5K ﹤0.01% 7668
2018
Q1 		$20K Buy
43
+28
+187% +$13.9K ﹤0.01% 6425
2017
Q4 		$9K Sell
15
-4
-21% -$2.64K ﹤0.01% 7112
2017
Q3 		$14K Buy
19
+16
+533% +$12.7K ﹤0.01% 6711
2017
Q2 		$2K Buy
3
+1
+50% +$731 ﹤0.01% 7412
2017
Q1 		$1K Hold
2
– – ﹤0.01% 7485
2016
Q4 		$1K Sell
2
-4
-67% -$3.25K ﹤0.01% 7661
2016
Q3 		$6K Buy
6
+4
+200% +$5.05K ﹤0.01% 7075
2016
Q2 		$2K Hold
2
– – ﹤0.01% 7459
2016
Q1 		$2K Hold
2
– – ﹤0.01% 7341
2015
Q4 		$2K Sell
2
-11
-85% -$14.3K ﹤0.01% 8043
2015
Q3 		$19K Sell
13
-4
-24% -$7.72K ﹤0.01% 6758
2015
Q2 		$36K Buy
17
+11
+183% +$34.5K ﹤0.01% 6312
2015
Q1 		$18K Sell
6
-4
-40% -$12.8K ﹤0.01% 7091
2014
Q4 		$33K Buy
+10
New +$35.4K ﹤0.01% 7008

Other funds holding FRTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

UBS Group's FRTX Position: Q2 2023 in Review

UBS Group sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q2 2023, closing a stake of 6,462 shares — an estimated $4.26K sold.

UBS Group first reported a position in FRTX in Q4 2014 and held it in 29 quarters. The position peaked at $95K in Q2 2021. 15 funds tracked by Wall St. Rank hold FRTX as of Q2 2023.

  • UBS Group reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • UBS Group sold 6,462 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $4.26K.
  • UBS Group first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q4 2014 and held it in 29 quarters.
  • UBS Group's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $95K in Q2 2021.
  • 15 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q2 2023.

Based on UBS Group's 13F filing for Q2 2023, filed 11 Aug 2023.